Key terms
About NBSE
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NBSE news
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 24
9:56am ET
NeuBase Therapeutics Plans Dissolution and Asset Liquidation
Jan 27
4:05am ET
NeuBase Therapeutics Strikes Definitive Warrant Agreement
No recent press releases are available for NBSE
NBSE Financials
Key terms
Ad Feedback
NBSE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NBSE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
